Sugi Predict

Sugi Predict / Compounds / SCHEMBL4086765

SCHEMBL4086765

SCHEMBL4086765

CCC(C)c1ccc(C(NC(=O)Nc2ccc(S(C)(=O)=O)cc2)c2ccc(C(=O)Nc3nn[nH]n3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ GCGR P47871 4/20 0.43
▸ ADCY6 O43306 1/20 0.43
▸ ADCY3 O60266 1/20 0.43
▸ ADCY9 O60503 1/20 0.43
▸ ADCY5 O95622 1/20 0.43
▸ ADCY8 P40145 1/20 0.43
▸ ADCY7 P51828 1/20 0.43
▸ ADCY2 Q08462 1/20 0.43
▸ ADCY1 Q08828 1/20 0.43
▸ ADCY4 Q8NFM4 1/20 0.43
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ XDH P47989 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4081625 0.90 ALDH1A1 (0.43) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4086760 0.81 GCGR (0.45) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL2564681 0.79 RAB9A (0.56) LMNANPC1RAB9AALDH1A1TP53
SCHEMBL4085620 0.79 CYSLTR2 (0.42) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4091978 0.78 GCGR (0.51) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4092326 0.77 LMNA (0.45) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4081375 0.76 TRPV1 (0.55) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4088384 0.76 GCGR (0.62) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL4092088 0.75 GCGR (0.47) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL4082222 0.75 GCGR (0.51) LMNAGCGRADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR LMNA 3643/4885GCGR 3/4885ADCY6 956/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR LMNA 3643/4885GCGR 3/4885ADCY6 956/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR LMNA 3643/4885GCGR 3/4885ADCY6 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.